ArticleFuture cardiology2025
OCT-Guided covered stent implantation for acquired coronary aneurysm after bioresorbable vascular scaffold: case report.
Article in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery aneurysm (CAA) formation following bioresorbable vascular scaffold (BVS) implantation is a rare but serious complication with no clear treatment guidelines. We report the case of a 56-year-old man with coronary artery disease (CAD) and a chronic total occlusion (CTO) in the left anterior descending artery (LAD) underwent full revascularization with BVS in 2016. Seven years later, he experienced recurrent angina, and angiography revealed 80% stenosis in the proximal LAD and a large coronary aneurysm in the middle LAD. Optical coherence tomography (OCT) confirmed a 5.88 mm aneurysm, which was treated with a PK Papyrus covered stent, while the proximal LAD stenosis was addressed with a Resolute Onyx drug-eluting stent (DES). After six months of standard dual antiplatelet therapy (DAPT) followed by three months of single antiplatelet therapy (SAPT), the patient developed in-stent restenosis (ISR) in the covered stent. This was successfully treated with high-pressure balloon angioplasty and a drug-eluting balloon (DEB). At the nine-month follow-up, the patient remained symptom-free. This case highlights the utility of OCT in evaluating CAAs and guiding covered stent deployment, while prolonged DAPT may help reduce the risk of very late stent thrombosis and future ischemic events, though further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.